@TIME 100 Health 2026. Physician-Scientist/Clinical Cancer Biologist/GI Medical Oncologist. In lab: Cancer Cell Biology, uncovering how #TunnelingNanotubes drive ChemoResistance. https://time.com/collections/time100-health-2026/
Emil Lou, MD, PhD, FACP, FASCO
With decades of research culminating in an explosive arrival this spring of clinical trial data for KRAS inhibitors, PBS NewsHour breaks it down in time for #ASCO26, thanks @pbsnews.org team for the opportunity.
www.pbs.org/newshour/hea...
Emil Lou, MD, PhD, FACP, FASCO
Lots of exciting advances coming through at @ascocancer.bsky.social 2026
A great meeting with @cancerassassin1.bsky.social regarding KLEOS, the new CCA trial platform
Research co-authored by MSK gastrointestinal medical oncologist Dr. Eileen O’Reilly will be presented during the plenary session at #ASCO26.
Cases of bowel cancer in young adults are increasing at an alarming rate: there are too many stories like Bradley's, a young man who died from bowel cancer in his early twenties. @icr.ac.uk are fundraising so we can lead more research to prevent and better treat bowel cancer at all ages.
Great discussion of current ASCO controversies by @cancerassassin1.bsky.social
Go watch the full episode when posted: youtube.com/@onlyoncs?si...
During this morning's Opening Session at #ASCO26, we were proud to see three past and present ACS grantees included in the newest class of Fellows of the @ascocancer.bsky.social:
- Dr. Chloe E. Atreya
- Dr. Areej El-Jawahri
- @cancerassassin1.bsky.social
Congrats to all on earning your #FASCO!
@cancerassassin1.bsky.social and I break down the implications of the recent RASolute 302 phase 3 clinical trial, and the impact it will have on the field:
ascopost.com/issues/june-...
We have more publications coming on the future of KRAS!
#ASCOPost #ASCO2026 #daraxonrasib #OncSky
Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says Dr. Shruti Patel in this Science in Seconds. #pancan
Read the abstract: https://bit.ly/4dChEWM
Ajay Prakash, MD, PhD
Ajay Prakash, MD, PhD
Ajay Prakash, MD, PhD
Memorial Sloan Kettering Cancer Center
American Cancer Society
Beyond the Data: How Physicians Talk to Patients About Uncertainty: #podcast episode from @nanets.bsky.social
Available here: podcasts.apple.com/us/podcast/b...
American Society of Clinical Oncology
Trevor Graham
My colleague GI Oncologist Dr. Ajay Prakash @cancertrials.bsky.social #UMN breaks it down for The
@ascopost.bsky.social @ascocancer.bsky.social
Published June 10, 2026:
Daraxonrasib in KRAS-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
ascopost.com/issues/june-...
Emil Lou, MD, PhD, FACP, FASCO
Emil Lou, MD, PhD, FACP, FASCO
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
Today we launch our appeal to give everyone with bowel cancer the hope of a cure.
Our world-class scientists are pushing the boundaries of research to shape a future in which bowel cancer is more preventable, predictable and treatable.
Please support us today: www.icr.ac.uk/support-us/o...
